Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

Lihi Eder, MD, PhD

University of Toronto
Toronto, ON, Canada

Dr. Eder has a broad background in rheumatology with specific training and expertise in psoriatic arthritis, musculoskeletal ultrasound, and cardiovascular diseases in rheumatic patients. She is the Director of the Psoriatic Arthritis program at Women’s College Hospital and co-Director of the University of Toronto Cardio-Rheumatology Program.
Dr. Eder’s research focuses on the transition from psoriasis to psoriatic arthritis, attempting to develop clinical and imaging tools to facilitate early diagnosis. She also studies the effect of cardio-metabolic abnormalities on the course of psoriatic disease and evaluates the effect of interventions to improve metabolic burden on cardiac, skin, and joint-related outcomes in this patient population.
Dr. Eder was awarded the Canada Research Chair in Inflammatory Rheumatic Diseases (2021-2026) for studying the effects of sex and gender as determinants of rheumatic disease outcomes.
Her research efforts have resulted in over 170 peer-reviewed publications in medical journals, book chapters, and editorials. As a recognized expert in rheumatology, she received a New Investigator Award from the Arthritis Society (2016), an Early Research Award from the Ontario Ministry of Research Innovation and Science (2018), and an Emerging Investigator Award from the Canadian Rheumatology Association (2023).

Presentation(s):

  • 0455: Assessment of Pain Outcomes in Pooled Phase 3 Trials of a Selective, Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients with Active Psoriatic Arthritis

    Sunday, October 26, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Novo Nordisk: Grant/Research Support (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 0522: The Incidence Rate and Risk Factors of Arrhythmias in Patients with Psoriatic Arthritis

    Sunday, October 26, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Novo Nordisk: Grant/Research Support (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • ITS12: Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition

    Sunday, October 26, 2025
    5:30 PM - 7:30 PM Central Time

    Disclosure information not submitted.

  • 0873: Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis

    Monday, October 27, 2025
    10:00 AM - 10:15 AM Central Time

    Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Novo Nordisk: Grant/Research Support (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 1714: The perimenopause period is associated with increased levels of disease activity in psoriatic arthritis

    Monday, October 27, 2025
    4:00 PM - 4:15 PM Central Time

    Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Novo Nordisk: Grant/Research Support (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 1959: The development and validation of a Diagnostic Ultrasound Enthesitis Score (DUET) for Psoriatic Arthritis

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Novo Nordisk: Grant/Research Support (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 2358: Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Novo Nordisk: Grant/Research Support (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 2356: Clinical Efficacy in Male and Female Patients With Active Psoriatic Arthritis Treated With Deucravacitinib: A Pooled Analysis of Pivotal Phase 3 Studies

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Novo Nordisk: Grant/Research Support (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 2357: Impact of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Active Psoriatic Arthritis: Key Subgroup Analyses in the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Novo Nordisk: Grant/Research Support (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 2687: Glucagon-like peptide-1 receptor agonists therapy is associated in improvement in psoriatic arthritis-related and metabolic outcomes: A retrospective analysis of two cohorts

    Wednesday, October 29, 2025
    11:30 AM - 11:45 AM Central Time

    Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Novo Nordisk: Grant/Research Support (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 2690: Dietary interventions in Psoriatic Arthritis: A Randomized controlled clinical trial

    Wednesday, October 29, 2025
    12:15 PM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Novo Nordisk: Grant/Research Support (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)